Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLT NYSE:AMPX NASDAQ:AVAV NASDAQ:CMPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLTAllot$8.16+2.8%$7.21$6.12▼$11.92$396.94M1.46487,262 shs363,859 shsAMPXAmprius Technologies$20.27-2.8%$18.09$2.55▼$22.80$2.87B2.210.03 million shs8.73 million shsAVAVAeroVironment$207.24-3.3%$185.32$156.00▼$417.86$10.35B1.351.23 million shs2.73 million shsCMPXCompass Therapeutics$2.38-1.2%$3.81$1.61▼$6.88$428.61M0.796.28 million shs6.03 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLTAllot+2.77%+5.97%+12.86%+28.71%-1.09%AMPXAmprius Technologies-4.89%+26.55%+0.20%+88.64%+582.46%AVAVAeroVironment-3.34%+18.95%+12.94%-17.84%+17.50%CMPXCompass Therapeutics-1.24%+14.98%+42.51%-57.88%+13.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLTAllot$8.16+2.8%$7.21$6.12▼$11.92$396.94M1.46487,262 shs363,859 shsAMPXAmprius Technologies$20.27-2.8%$18.09$2.55▼$22.80$2.87B2.210.03 million shs8.73 million shsAVAVAeroVironment$207.24-3.3%$185.32$156.00▼$417.86$10.35B1.351.23 million shs2.73 million shsCMPXCompass Therapeutics$2.38-1.2%$3.81$1.61▼$6.88$428.61M0.796.28 million shs6.03 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLTAllot+2.77%+5.97%+12.86%+28.71%-1.09%AMPXAmprius Technologies-4.89%+26.55%+0.20%+88.64%+582.46%AVAVAeroVironment-3.34%+18.95%+12.94%-17.84%+17.50%CMPXCompass Therapeutics-1.24%+14.98%+42.51%-57.88%+13.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLTAllot 2.57Moderate Buy$13.6366.97% UpsideAMPXAmprius Technologies 2.78Moderate Buy$20.25-0.09% DownsideAVAVAeroVironment 2.88Moderate Buy$318.7853.82% UpsideCMPXCompass Therapeutics 2.86Moderate Buy$13.60471.43% UpsideCurrent Analyst Ratings BreakdownLatest CMPX, AVAV, ALLT, and AMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026ALLTAllot Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$15.005/13/2026ALLTAllot Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.50 ➝ $10.505/11/2026AMPXAmprius Technologies Northland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/8/2026AMPXAmprius Technologies Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/4/2026AVAVAeroVironment Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026AVAVAeroVironment Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/27/2026CMPXCompass Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLTAllot$101.99M3.89$0.20 per share39.85$2.37 per share3.44AMPXAmprius Technologies$73.01M39.32N/AN/A$0.77 per share26.32AVAVAeroVironment$820.63M12.61$5.41 per share38.31$31.36 per share6.61CMPXCompass Therapeutics$850K504.25N/AN/A$1.04 per share2.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLTAllot$3.70M$0.1362.7725.50N/A5.68%7.38%4.70%8/13/2026 (Estimated)AMPXAmprius Technologies-$44.02M-$0.30N/A289.56N/A-43.98%-17.48%-12.11%8/6/2026 (Estimated)AVAVAeroVironment$43.62M-$4.34N/A55.562.84-13.93%3.26%2.56%6/29/2026 (Estimated)CMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%8/10/2026 (Estimated)Latest CMPX, AVAV, ALLT, and AMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/23/2026Q4 2026AVAVAeroVironment$1.47N/AN/AN/A$557.17 millionN/A5/12/2026Q1 2026ALLTAllot$0.05$0.06+$0.01$0.04$26.12 million$26.43 million5/6/2026Q1 2026AMPXAmprius Technologies-$0.02-$0.04-$0.02-$0.04$25.72 million$28.54 million5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A3/31/2026Q1 2026ALLTAllotN/A$0.06N/A$0.04N/A$26.43 million3/10/2026Q3 2026AVAVAeroVironment$0.68$0.64-$0.04-$3.15$487.94 million$408.05 million3/5/2026Q4 2025CMPXCompass Therapeutics-$0.10-$0.09+$0.01-$0.09($0.90) millionN/A3/4/2026Q4 2025AMPXAmprius Technologies-$0.04-$0.01+$0.03-$0.18$22.91 million$25.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLTAllotN/AN/AN/AN/AN/AAMPXAmprius TechnologiesN/AN/AN/AN/AN/AAVAVAeroVironmentN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLTAllotN/A2.392.13AMPXAmprius TechnologiesN/A7.136.61AVAVAeroVironment0.175.514.54CMPXCompass TherapeuticsN/A19.0419.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLTAllot51.50%AMPXAmprius Technologies5.04%AVAVAeroVironment86.38%CMPXCompass Therapeutics68.43%Insider OwnershipCompanyInsider OwnershipALLTAllot3.40%AMPXAmprius Technologies5.10%AVAVAeroVironment0.81%CMPXCompass Therapeutics18.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLTAllot74048.65 million46.99 millionOptionableAMPXAmprius Technologies50141.63 million134.40 millionOptionableAVAVAeroVironment1,47549.93 million49.53 millionOptionableCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionableCMPX, AVAV, ALLT, and AMPX HeadlinesRecent News About These CompaniesCompass Therapeutics to Participate in Upcoming June Investor EventsMay 28 at 7:30 AM | globenewswire.comCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ...May 23, 2026 | markets.businessinsider.comCompass Therapeutics Eyes FDA Meeting, BLA for Tovecimig as Pipeline Updates NearMay 23, 2026 | americanbankingnews.comCompass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced MalignanciesMay 21, 2026 | quiverquant.comQCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 21, 2026 | prnewswire.comCompass Therapeutics Backs Tovecimig Data, Eyes FDA Meeting This SummerMay 21, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 19, 2026 | globenewswire.comCompass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3MMay 18, 2026 | finance.yahoo.comCompass Therapeutics (CMPX) price target decreased by 26.39% to 10.11May 16, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 14, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 12, 2026 | globenewswire.comCompass Therapeutics to Participate in Upcoming May Investor EventsMay 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Compass Therapeutics (CMPX) and Addus Homecare (ADUS)May 8, 2026 | theglobeandmail.comQ3 EPS Forecast for Compass Therapeutics Lifted by AnalystMay 8, 2026 | marketbeat.comGuggenheim Remains a Buy on Compass Therapeutics (CMPX)May 7, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 7, 2026 | prnewswire.comHC Wainwright Issues Negative Forecast for CMPX EarningsMay 7, 2026 | marketbeat.comCompass Therapeutics (CMPX) to Release Earnings on ThursdayMay 7, 2026 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 7, 2026 | marketbeat.comCanaccord Maintains Buy Rating on Compass Therapeutics (CMPX)May 5, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Amprius Technologies Ups the Voltage on Forward OutlookBy Thomas Hughes | May 7, 2026CMPX, AVAV, ALLT, and AMPX Company DescriptionsAllot NASDAQ:ALLT$8.16 +0.22 (+2.77%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$8.07 -0.09 (-1.05%) As of 05/29/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allot Communications Ltd. is a provider of leading innovative network intelligence and security solutions for service providers worldwide, enhancing value to their customers. Their solutions are deployed globally for network and application analytics, traffic control and shaping, network-based security services, and more. Allot's multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Their industry leading network-based security as a service solution has achieved over 50% penetration with some service providers and is already used by over 20 million subscribers in Europe.Amprius Technologies NYSE:AMPX$20.27 -0.58 (-2.79%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$20.23 -0.04 (-0.19%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amprius Technologies, Inc. produces and sells ultra-high energy density lithium-ion batteries for mobility applications. The company offers silicon nanowire anode batteries. Its batteries are primarily used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. The company was incorporated in 2008 and is headquartered in Fremont, California.AeroVironment NASDAQ:AVAV$207.24 -7.15 (-3.34%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$207.92 +0.68 (+0.33%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AeroVironment, Inc. designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses in the United States and internationally. It operates through Small Unmanned Aircraft Systems (SUAS), Tactical Missile System (TMS), Medium Unmanned Aircraft Systems (MUAS), and High Altitude Pseudo-Satellite Systems (HAPS) segments. The company supplies UAS, TMS, unmanned ground vehicle, and related services primarily to organizations within the U.S. Department of Defense, other federal agencies, and to international allied governments. It also designs, engineers, tools, and manufactures unmanned aerial and aircraft systems, including airborne platforms, payloads and payload integration, ground control systems, and ground support equipment and other items and services related to unmanned aircraft systems. In addition, the company offers small UAS products, including training, spare parts, product repair, product replacement, and the customer contracted operation. Further, it develops high-altitude pseudo-satellite UAS systems. AeroVironment, Inc. was incorporated in 1971 and is headquartered in Arlington, Virginia.Compass Therapeutics NASDAQ:CMPX$2.38 -0.03 (-1.24%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.37 -0.01 (-0.63%) As of 05/29/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
